The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima
dc.contributor.author | Stenning Persivale, Karoline Andrea | * |
dc.contributor.author | Savitzky Franco, Maria Jose | * |
dc.contributor.author | Cordero-Morales, Alejandra | * |
dc.contributor.author | Cruzado-Burga, José | * |
dc.contributor.author | Poquioma, Ebert | * |
dc.contributor.author | Díaz Nava, Edgar | * |
dc.contributor.author | Payet, Edouardo | * |
dc.date.accessioned | 2018-02-12T14:57:26Z | |
dc.date.available | 2018-02-12T14:57:26Z | |
dc.date.issued | 2018-01-18 | |
dc.identifier.citation | The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima 2018, 12 ecancermedicalscience | es |
dc.identifier.issn | 17546605 | |
dc.identifier.doi | 10.3332/ecancer.2018.799 | |
dc.identifier.uri | http://hdl.handle.net/10757/622636 | |
dc.description.abstract | Introduction: The Mortality–Incidence Ratio complement [1 – MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima. Materials and methods: The Metropolitan Lima Cancer Registry (RCLM in Spanish) for 2004–2005 was used to determine the number of new cases and the number of deaths of the following cancers: breast, stomach, prostate, thyroid, lung, colon, cervical, and liver cancers, as well as non-Hodgkin’s lymphoma and leukaemia. To determine the five-year survival, the five-year vital status of cases recorded was verified in the National Registry of Identification and Civil Status (RENIEC in Spanish). A linear regression model was used to assess the correlation between [1 – MIR] and total observed five-year survival for the selected cancers. Results: Observed and estimated five-year survival determined by [1 – MIR] for each neoplasia were thyroid (66.7%, 86.7%), breast (69.6%; 68%), prostate (64.3%, 63.8%) and cervical (50.1%, 58.5%), respectively. Pearson’s r coefficient for the correlation between [MIR – 1] and observed survival was = 0.9839. Using the coefficient of determination, it was found that [1 – MIR] (X) captures the 96.82% of observed survival (Y). Conclusion: The Mortality–Incidence Ratio complement [1 – MIR] is an appropriate tool for approximating observed five-year survival for the ten types of cancers studied. This study demonstrates the validity of this model for predicting five-year survival in cancer patients in metropolitan Lima. | |
dc.format | application/pdf | es |
dc.language.iso | eng | es |
dc.publisher | Cancer Intelligence | es |
dc.relation.url | http://www.ecancer.org/journal/12/full/799-the-mortality-incidence-ratio-as-an-indicator-of-five-year-cancer-survival-in-metropolitan-lima.php | es |
dc.rights | info:eu-repo/semantics/openAccess | es |
dc.subject | Cancer | es |
dc.subject | Cancer registries | es |
dc.subject | Incidence | es |
dc.subject | Mortality | es |
dc.subject | Mortality/incidence ratio | es |
dc.subject | Peru | es |
dc.subject | Survival | es |
dc.title | The mortality-incidence ratio as an indicator of five-year cancer survival in metropolitan Lima | es |
dc.type | info:eu-repo/semantics/article | es |
dc.identifier.journal | ecancermedicalscience | es |
dc.description.funding | We would like to thank the Department of Epidemiology and Statistics of the National Cancer Institute (INEN) and the entire departmental staff. | es_PE |
dc.description.peerreview | Revisión por pares | es_PE |
refterms.dateFOA | 2018-06-15T20:30:49Z | |
html.description.abstract | Introduction: The Mortality–Incidence Ratio complement [1 – MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima. Materials and methods: The Metropolitan Lima Cancer Registry (RCLM in Spanish) for 2004–2005 was used to determine the number of new cases and the number of deaths of the following cancers: breast, stomach, prostate, thyroid, lung, colon, cervical, and liver cancers, as well as non-Hodgkin’s lymphoma and leukaemia. To determine the five-year survival, the five-year vital status of cases recorded was verified in the National Registry of Identification and Civil Status (RENIEC in Spanish). A linear regression model was used to assess the correlation between [1 – MIR] and total observed five-year survival for the selected cancers. Results: Observed and estimated five-year survival determined by [1 – MIR] for each neoplasia were thyroid (66.7%, 86.7%), breast (69.6%; 68%), prostate (64.3%, 63.8%) and cervical (50.1%, 58.5%), respectively. Pearson’s r coefficient for the correlation between [MIR – 1] and observed survival was = 0.9839. Using the coefficient of determination, it was found that [1 – MIR] (X) captures the 96.82% of observed survival (Y). Conclusion: The Mortality–Incidence Ratio complement [1 – MIR] is an appropriate tool for approximating observed five-year survival for the ten types of cancers studied. This study demonstrates the validity of this model for predicting five-year survival in cancer patients in metropolitan Lima. |
Files in this item
This item appears in the following Collection(s)
-
Medicina [970]